Immatics Gross Profit Trend from 2010 to 2022

IMTX -  USA Stock  

USD 7.06  0.45  6.81%

Immatics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 31.1 M in 2022. During the period from 2010 to 2022, Immatics Gross Profit regression line of anual values had slope of 2,597,346 and arithmetic mean of  11,497,090. Immatics Interest Expense is fairly stable at the moment as compared to the past year. Immatics reported Interest Expense of 1.73 Million in 2021. Net Income to Non Controlling Interests is likely to rise to about 598.4 K in 2022, whereas Consolidated Income is likely to drop (100.7 M) in 2022.
  
Refresh
Check Immatics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics main balance sheet or income statement drivers, such as Gross Profit of 31.1 M, Interest Expense of 2.7 M or Net Income to Non Controlling Interests of 598.4 K, as well as many exotic indicators such as Asset Turnover of 0.18, Book Value per Share of 0.41 or Current Ratio of 1.74. Immatics financial statements analysis is a perfect complement when working with Immatics Valuation or Volatility modules. It can also supplement various Immatics Technical models. Please see the analysis of Immatics Correlation against competitors.

Immatics Quarterly Gross Profit

15.73 Million

Share

Immatics Gross Profit Breakdown

Showing smoothed Gross Profit of Immatics NV with missing and latest data points interpolated. Gross profit is a required income statement account that reflects total revenue of Immatics NV minus its cost of goods sold. It is profit before Immatics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. Aggregate revenue Revenues less cost of revenue [CoR] directly attributable to the revenue generation activity.Immatics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (52.81 M)10 Years Trend
Increasing
Slightly volatile
 Gross Profit 
Share
      Timeline 

Immatics Gross Profit Regression Statistics

Arithmetic Mean 11,497,090
Geometric Mean 6,993,904
Coefficient Of Variation 109.45
Mean Deviation 10,699,048
Median 3,770,000
Standard Deviation 12,584,008
Range 30,993,000
R-Value 0.80
R-Squared 0.65
Significance 0.0009291
Slope 2,597,346

Immatics Gross Profit History

201918.4 M
202031.3 M
202134.8 M
202231.1 M

About Immatics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immatics income statement, its balance sheet, and the statement of cash flows. Immatics investors use historical funamental indicators, such as Immatics's Gross Profit, to determine how well the company is positioned to perform in the future. Although Immatics investors may use each financial statement separately, they are all related. The changes in Immatics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immatics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immatics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immatics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Gross Profit34.8 M31.1 M
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor based immunotherapies for the treatment of cancer in the United States. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers and Genmab AS to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 188 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immatics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Risk-Return Analysis Now

   

Risk-Return Analysis

View associations between returns expected from investment and the risk you assume
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immatics NV using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immatics Correlation against competitors. Note that the Immatics NV information on this page should be used as a complementary analysis to other Immatics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Immatics Stock analysis

When running Immatics NV price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Immatics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immatics. If investors know Immatics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immatics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immatics NV is measured differently than its book value, which is the value of Immatics that is recorded on the company's balance sheet. Investors also form their own opinion of Immatics' value that differs from its market value or its book value, called intrinsic value, which is Immatics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immatics' market value can be influenced by many factors that don't directly affect Immatics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immatics' value and its price as these two are different measures arrived at by different means. Investors typically determine Immatics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immatics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.